Literature DB >> 3790146

The metabolic chiral inversion of 2-phenylpropionic acid in rat, mouse and rabbit.

S Fournel, J Caldwell.   

Abstract

The metabolic chiral inversion of the 2-arylpropionic acids has been investigated in laboratory animals, using the simplest congener, 2-phenylpropionic acid, as a model compound. The chiral inversion was found to occur after administration of the racemate to the rat and rabbit, but not in the mouse. The formation of the ester glucuronide was enantioselective for the S-(-)-isomer in the rat and mouse, but showed no stereoselectivity in the rabbit. [corrected] In the rat, the extent of inversion from R-(-) to S-(+) was greater at a dose of 30 mg/kg than at 150 or 300 mg/kg. The enantiomeric composition of the acid in urine was the same when the racemate was given orally or by i.p. injection. When the R-(-)isomer was given to rats, some 30% of the excreted acid was in the S-(+)-form, but when the S-(+)-isomer was given, the inversion was much less evident. In this case, the S/R ratio of the excreted phenylproprionic acid was ca 9:1. Following the administration of the racemate to rats, the plasma elimination half-life of the R-(-)-form was shorter (3.0 vs 4.8 hr for the S-(-)-isomer); this was due to its considerably greater plasma clearance (65.9 vs 43.6 micrograms/ml hr), since the volumes of distribution of the enantiomers were the same. The S/R ratio of 2-phenylpropionic acid in plasma rose progressively with time, from 1:1 in the dose solution to 2.1:1 at 8 hr.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790146     DOI: 10.1016/0006-2952(86)90689-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.

Authors:  F Lapicque; N Muller; E Payan; N Dubois; P Netter
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

3.  Stereoselective disposition of ibuprofen enantiomers in the isolated perfused rat kidney.

Authors:  H Y Ahn; F Jamali; S R Cox; D Kittayanond; D E Smith
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

4.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

5.  The in vitro metabolic inversion of R(-) to S(+) indoprofen.

Authors:  V Rossetti; A Lombard; M Buffa; A Miglietta; A Oliviero; E Gadoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

6.  Pharmacokinetics of the enantiomers of ibuprofen in the rabbit.

Authors:  K M Williams; R D Knihinicki; R O Day
Journal:  Agents Actions       Date:  1991-11

Review 7.  The safety evaluation of food flavouring substances: the role of metabolic studies.

Authors:  Robert L Smith; Samuel M Cohen; Shoji Fukushima; Nigel J Gooderham; Stephen S Hecht; F Peter Guengerich; Ivonne M C M Rietjens; Maria Bastaki; Christie L Harman; Margaret M McGowen; Sean V Taylor
Journal:  Toxicol Res (Camb)       Date:  2018-03-28       Impact factor: 3.524

8.  A new method for production of chiral 2-aryl-2-fluoropropanoic acids using an effective kinetic resolution of racemic 2-aryl-2-fluoropropanoic acids.

Authors:  Atsushi Tengeiji; Isamu Shiina
Journal:  Molecules       Date:  2012-06-14       Impact factor: 4.411

9.  A thorough analysis of the effect of surfactant/s on the solubility and pharmacokinetics of (S)-zaltoprofen.

Authors:  Cuong Viet Pham; Jong-Suep Baek; Jong-Hun Park; Sang-Hun Jung; Jong-Seong Kang; Cheong-Weon Cho
Journal:  Asian J Pharm Sci       Date:  2018-11-02       Impact factor: 6.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.